WP:COPYARTICLE, old revision of Revolution Medicines which has been deleted, see User talk:GLBIV
| Company type | Public |
|---|---|
| Nasdaq: RVMD | |
| Founded |
|
| Headquarters | Redwood City, California |
Key people |
|
| Website |
revmed |
Revolution Medicines is a publicly traded (NASDAQ:RVMD) [1] precision medicine biotechnology company that is focused on developing novel therapies for frontier oncology targets, and is focused on the RAS cancer pathway. Their clinical-stage SHP2 inhibitor, RMC-4630, is currently in Phase 1/2, and is facilitated through a partnership with Sanofi [2] [3] Revolution Medicines showed that SHP2 inhibition is an effective form of treatment in cancers with RAS-GTP dependent oncogenic BRAF and NF1 loss of function. [4] [5] Revolution Medicine's recently announced a Phase 1B combination study of RMC-4630 with Amgen's AMG 510. [6] [7]
The company's current platform leverages bRo5 compounds to target various mutant RAS proteins through inhibition of the RAS(ON) state. [8] [9]
References
- ^ "Revolution Medicines, Inc". NASDAQ.com.
- ^ "Sanofi and REVOLUTION Medicines Launch Global Partnership to Develop Potential First-in-Class Targeted Treatments for Multiple Cancers".
- ^ "Sanofi pays $50 million for Revolution Medicines' SHP2 inhibitor".
- ^ "Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss".
- ^ "RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers".
- ^ "Revolution Medicines And Amgen Partner On Phase 1B Study To Evaluate Combination Of RMC-4630 And AMG 510".
- ^ "Cracking KRAS".
- ^ "REVOLUTION Medicines Acquires Warp Drive Bio to Expand Drug Discovery Portfolio Focused on Frontier Oncology Targets".
- ^ "Revolution Medicines to absorb Warp Drive Bio into its oncology and 'undruggable' discovery efforts".
Category:Companies listed on the Nasdaq Category:Biotechnology companies of the United States